Oncternal Therapeutics, Inc. (ONCT)

Market Cap	51.27M
Revenue (ttm)	1.49M
Net Income (ttm)	-44.17M
Shares Out	58.71M
EPS (ttm)	-0.84
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	178,778
Open	0.869
Previous Close	0.878
Day's Range	0.840 - 0.882
52-Week Range	0.600 - 1.870
Beta	1.34
Analysts	Buy
Price Target	8.42 (+864.16%)
Earnings Date	May 4, 2023

About ONCT

Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins. It is also developing ONCT-808, a chimeric antigen receptor T-cells (CAR-T) product candidate that targets R...

• Industry: Biotechnology
• Sector: Healthcare
• CEO: James Breitmeyer
• Employees: 26
• Stock Exchange: NASDAQ
• Ticker Symbol: ONCT

Financial Performance

In 2022, ONCT's revenue was $1.49 million, a decrease of -65.47% compared to the previous year's $4.32 million. Losses were -$44.17 million, 41.0% more than in 2021.

Analyst Forecast

According to 13 analysts, the average rating for ONCT stock is "Buy." The 12-month stock price forecast is $8.42, which is an increase of 864.16% from the latest price.

Price Target

$8.42

(864.16% upside)

Analyst Consensus: Buy